Recro Pharma's pain treatment clears Phase II; GSK and Immunocore move forward in lung cancer;

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Vtesse gets a BTD on Niemann Pick drug. Release | Follow @JohnCFierce

@DamianFierce: man with lots of money has no regrets about making more of it. More from Bloomberg | Follow @DamianFierce

> Recro Pharma ($REPH) posted positive Phase II results for its intravenous treatment for post-surgical pain, putting the company on track to start Phase III development later this quarter. More

> GlaxoSmithKline ($GSK) and oncology partner Immunocore have selected their first candidate in a T cell receptor alliance, planning a clinical trial in non-small cell lung cancer. Item

> ChemoCentryx's ($CCXI) lead treatment met its primary endpoint in a Phase II treatment on the rare anti-neutrophil cytoplasmic antibody-associated vasculitis, and the company is planning a Phase III study later this year. News

Medical Device News

@FierceMedDev: Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: This question has been on my mind for a while. What does the "F" in F. Michael Ball stand for? More | Follow @EmilyWFierce

@VarunSaxena2: Medtronic CEO ambivalent about competing with Google, despite budding robotic surgery rivalry. FierceMedicalDevices story | Follow @VarunSaxena2

> Brain app startup settles with FTC over false product claims. Article

> Benvenue secures $60M in debt and equity to accelerate commercialization of its spinal implants. More

> NEA partner outlines challenging med tech VC landscape heading into 2016. Editor's corner

Pharma News

@FiercePharma: Study finds some docs are not strongly recommending HPV vaccines for preteens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. Article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson. Report | Follow @CarlyHFierce

> Takeda snatches Baxalta plant to produce Entyvio in U.S. Story

> No M&A? No problem, Actelion says as it rolls out $160K-plus Uptravi. Article

> Rapid-fire pharma M&A could stall a bit in 2016: Bloomberg. More

Biotech Research News

> Cannabinoid drug reduces epileptic seizures in hard-to-treat children. Item

> CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy. Report

> Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease. More

> Gut bacteria plays a big role in regulating impact of anti-inflammatory NSAIDs. Story

> UNC team spotlights Dicer as a new target for brain cancers. Article

Vaccines News

> Study finds some docs are not strongly recommending HPV vaccines for preteens. More

> Bavarian Nordic files for Nasdaq IPO. News

> Emergex to use Midatech nanoparticle tech for vaccines against infectious diseases. Story

> Norway's Bionor tests drug-vaccine combo against HIV. Item

> China approves Sinovac's vaccine for hand, foot and mouth disease. Article

Pharma Marketing News

> Actelion slaps $160K-plus price tag on new PAH med Uptravi. Item

> Native advertising for pharma: Winning format or slippery slope to regulatory headaches? Report

> Boosted by CV data, Lilly's Jardiance grabs market share from J&J, AZ. Story

> FDA sends fewer drug promotion action letters in 2015--but is that a good thing for pharma? More

> Novartis matches respiratory rivals with 'smart inhaler' collaboration. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.